Xpert® bladder Cancer monitor urine test for non-muscle-invasive bladder cancer surveillance: a prospective clinical trial.
Clin Chim ActaJun 12, 2026 (epub)
Clinical ResearchUrology
Mohamed Trabelssi, Pierre-Jean Lamy, Jean-Pierre Daures et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective clinical trial evaluated the Xpert® Bladder Cancer Monitor test for monitoring non-muscle-invasive bladder cancer (NMIBC) in 193 patients over 18 months. The test demonstrated a sensitivity of 83.3%, significantly higher than the 33.3% sensitivity of urine cytology (p = 0.0015).
Key findings
- Xpert® Bladder Cancer Monitor test sensitivity was 83.3%, compared to 33.3% for urine cytology.
- The positive predictive value of the Xpert® test was 27.78%, while the negative predictive value was 97.32%.
- Histologically proven NMIBC recurrence was detected in 24 out of 221 tested cases.
Why it matters
The Xpert® Bladder Cancer Monitor test offers a non-invasive alternative for NMIBC surveillance, potentially improving detection rates of cancer recurrence compared to traditional methods.